Omega Diagnostics (CNSL) AI Stock Analysis

• Market Cap: £6.31M
• Dividend Yield: N/A
• Average Volume (3M): 254.06K
• Price to Earnings (P/E): 4.0
• Beta (1Y): 1.15
• Revenue Growth: -14.77%
• EPS Growth: N/A
• Country: UK
• Employees: 94
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 237,950,650
• 10 Day Avg. Volume: 173,478
• 30 Day Avg. Volume: 254,062
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.87
• P/FCF Ratio: -51.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: 3.00p ▲(13.21% Upside)

Omega Diagnostics' overall stock score reflects a challenging financial and technical outlook. The most significant factor is the mixed financial performance, with profitability overshadowed by declining revenue and cash flow issues. Technical analysis indicates bearish momentum, further weighing down the score. The stock's valuation suggests it may be undervalued, providing a potential opportunity for value investors.

Omega Diagnostics Business Overview & Revenue Model

Company Description

Cambridge Nutritional Sciences plc, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market. The company is involved in the research, development, and production of kits for detection of immune reactions to food under the Foodprint name. It provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The company serves government, private hospitals, reference laboratories, nutritionists, naturopaths, and other healthcare professionals. Cambridge Nutritional Sciences plc operates in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc was founded in 1987 and is based in London, the United Kingdom.

How the Company Makes Money

Omega Diagnostics generates revenue through the sale of its diagnostic products, which are marketed to hospitals, laboratories, and healthcare providers. The company has established key revenue streams from the distribution of its allergy testing kits and infectious disease diagnostics, which are often sold directly to healthcare facilities or through third-party distributors. Additionally, Omega may benefit from partnerships with other companies in the healthcare and diagnostics sectors, which can provide access to new markets and enhance its product offerings. The ongoing demand for accurate diagnostic testing in the healthcare industry, particularly in light of emerging health challenges, plays a significant role in sustaining and growing its earnings.

Omega Diagnostics Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.33M	8.33M	9.77M	7.55M	8.54M	6.82M
Gross Profit	5.00M	5.00M	6.05M	3.17M	4.75M	4.00M
EBITDA	2.20M	2.20M	-73.00K	-2.65M	-382.00K	418.00K
Net Income	1.57M	1.57M	-328.00K	-3.86M	-11.33M	-2.10M
Balance Sheet
Total Assets	13.80M	13.80M	13.89M	14.40M	17.84M	29.55M
Cash, Cash Equivalents and Short-Term Investments	4.87M	4.87M	5.44M	5.12M	1.60M	5.83M
Total Debt	349.00K	349.00K	148.00K	74.00K	370.00K	2.84M
Total Liabilities	2.39M	2.39M	4.21M	4.45M	6.02M	6.16M
Stockholders Equity	11.41M	11.41M	9.68M	9.95M	11.82M	23.38M
Cash Flow
Free Cash Flow	-142.00K	-142.00K	548.00K	-3.31M	-4.71M	-5.24M
Operating Cash Flow	83.00K	83.00K	607.00K	-3.15M	-3.23M	-2.42M
Investing Cash Flow	2.12M	2.12M	-2.51M	5.18M	-493.00K	-2.83M
Financing Cash Flow	-251.00K	-251.00K	-265.00K	1.49M	-502.00K	11.07M

Omega Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CNSL, the sentiment is Negative. The current price of 2.65 is below the 20-day moving average (MA) of 2.73, below the 50-day MA of 2.96, and below the 200-day MA of 3.19, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 32.43 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CNSL.

Omega Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSTL	―	£176.66M	26.58	20.31%	3.77%	10.80%	1.75%
EKF	―	£116.49M	19.52	8.71%	―	-1.43%	28.57%
RUA	―	£7.45M	1,200.00	0.08%	―	87.72%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNSL	―	£6.31M	4.02	14.85%	―	-14.77%	―
FDBK	―	£4.05M	―	-105.98%	―	-25.05%	-5.74%

Omega Diagnostics Corporate Events

Cambridge Nutritional Sciences Announces AGM and Annual Report Release

Cambridge Nutritional Sciences plc has announced the finalization of its Notice of Annual General Meeting and the Annual Report and Accounts for the year ending March 31, 2025. The AGM is scheduled for September 25, 2025, and the Annual Report will be distributed to shareholders and made available on the company’s website. This announcement underscores the company’s commitment to transparency and engagement with its stakeholders.

Cambridge Nutritional Sciences Grants Share Options to CFO

Cambridge Nutritional Sciences Plc has announced the granting of share options to Ajay Patel, the Chief Financial Officer and Executive Director. The grant includes 1,200,000 options over ordinary shares, which are subject to specific time conditions and Ajay Patel’s continued role as a director. This move is part of the company’s ongoing efforts to align executive incentives with shareholder interests, potentially impacting the company’s operational focus and market positioning.

Cambridge Nutritional Sciences PLC Reports Strong Financial Performance Amidst Strategic Restructuring

Cambridge Nutritional Sciences PLC reported its final results for the year ending March 31, 2025, highlighting a 12.7% increase in total income to £11.1 million, despite a 14.8% drop in revenues. The company achieved a significant improvement in gross margin to 65.3% and a 310% growth in profit before taxation. Operational improvements, including enhanced productivity and reduced scrap yields, have been pivotal in driving these financial gains. The company has also strengthened its leadership team and invested in automation to boost productivity and reduce costs. The strategic focus on core products and markets, along with a commitment to distributor partnerships and practitioner education, has positioned the company for future growth. The leadership changes, including the appointment of a new CEO and other key roles, are expected to further drive the company’s transformation and market expansion.

Cambridge Nutritional Sciences to Announce Final Results and Host Investor Presentation

Cambridge Nutritional Sciences plc announced it will release its final results for the year ending 31 March 2025 on 19 August 2025. The company will host an online investor presentation on the same day, led by CEO James Cooper and CFO Ajay Patel, to discuss the results, allowing shareholders to submit questions in advance or during the event.